NYSE:HUMHealthcare
Humana (HUM) Could Be 25% Overvalued As GAAP EPS Guidance Falls While Adjusted Outlook Holds
Humana (HUM) is in focus after reporting second quarter results, appointing two new directors and lowering full year 2026 GAAP EPS guidance to at least US$6.52 from at least US$8.36.
See our latest analysis for Humana.
The recent second quarter report and board additions have arrived during a strong run in Humana’s stock, with a 45.57% year to date share price return and a 46.45% 1 year total shareholder return, although the 3 year total shareholder return is down 19.17%.
If Humana’s latest...